Daniel Mahony’s Post

In this New Statesman Spotlight podcast, hear Stephen Aherne, Pharmaceutical and Life Sciences Leader, PwC UK, Chi Onwurah Shadow Minister Science, Research and Innovation and Dan Mahony - Chair of the BioIndustry Association (BIA) & Life Sciences Envoy for the UK Government, talk about how the UK could become a global life sciences superpower. Featuring findings from PwC's Life Sciences Future50 report, the discussion explores how to achieve that goal through strategies like: ⬆️ Boosting late-stage funding for UK innovators 💴 Building funding support among UK investors 🔬Increasing analyst research coverage to highlight investment opportunities 👩🏾🔬Expanding available infrastructure for labs and research Listen to the podcast now. #LifeScienceFuture50 #LifeSciences #Science #Pharmaceutical #Investment #Equities #Funding

Learn the three core principles of successfully implementing Industry 4.0 from our President/CEO, Ryan Schroeder. In his second article as part of the Forbes Business Council, Ryan shares insights he has gathered from conversations with senior leaders in the life sciences industry on Industry 4.0 and how creating a technology-driven ecosystem can help increase manufacturing efficiency to deliver more novel therapies to patients. Read it here: https://hubs.la/Q026gMrm0 To learn more about how Industry 4.0 is driving the life sciences industry forward, as well as other key trends and challenges biopharma companies are facing, download the 2023 Horizons: Life Sciences report: https://hubs.la/Q026gTc30 #LifeSciences #Industry40 #Biopharma #ForbesBusinessCouncil #CRBHorizons

As biopharma companies look to new markets for growth, leaders need to tailor the expansion approach to the nuances of each market. Check out this article, “Key Steps For Improving Biopharma Expansion Into New Markets,” co-authored by my colleagues Ranu Nandy Carroll and Arda Ural, MSc, MBA, PhD. #buildingabetterworkingworld #lifesciences

🤔 Is the Supply Chain the Hidden Pulse of Life Sciences?🤔 … Europe’s Pharmaceutical Strategy is a transformative blueprint by the European Commission, aiming to revitalize life sciences and bolster the supply chain. It’s a holistic approach to rejuvenate healthcare in Europe, ensuring equal access to therapies and addressing medicine shortages and accessibility challenges. 🌿 💡 Strategic Landscape: It’s a nourishing rain for life sciences, promising to breathe life into the sector and ensuring innovations flow seamlessly. 🌿 💡 Flexibility and Resilience: Balancing these is crucial in life sciences. The strategy aims for a delicate balance, creating value and ensuring innovations reach every corner of the sector. 🌿 💡 Supply Chain Strength: A resilient supply chain is vital, and the strategy fortifies this chain, preventing disruptions and ensuring a steady flow of innovations. 🌿 💡 Sustainability and Collaboration: Emphasized as means of benefit, it’s about creating a symbiotic coexistence within the sector, where sustainability is a source of value. 🌿 💡 Unified Approach: It brings a structured approach to addressing challenges, ensuring the ecosystem remains robust, delivering medicines seamlessly to patients in need. 🌿 For a deeper insight, read my attest article at DataDrivenInvestor: Innovating Life Sciences with Europe’s Pharmaceutical Strategy #LifeSciences #Innovation #PharmaceuticalStrategy #SupplyChain #Resilience #Sustainability [https://lnkd.in/eViyyiVK] #LifeSciences #Innovation #SupplyChain #PharmaceuticalStrategy #EuropeanCommission #medium

The 2024 strategy for the life sciences industry is likely to revolve around the integration of GenAI, addressing the challenges of drug pricing, and adapting to the evolving economic landscape. Successful navigation of these factors will be essential for companies to stay competitive and contribute to advancements in healthcare. 📚 Read on for more information. Share your thoughts with us. https://lnkd.in/eazp4uUU #biotech #innovation #research

What does the future hold for the Clinical Laboratory Market? Our latest market research report has the answers. From emerging technologies to changing consumer preferences, we've analyzed the trends that will shape the industry in the coming years. Don't miss out on this exclusive look into the future. Key Market Players- QIAGEN, Quest Diagnostics, OPKO Health, Inc., Abbott, Siemens, NeoGenomics Laboratories, Fresenius Medical Care North America, ARUP Laboratories, Sonic Healthcare, Labcorp & Others. Contact - sneha.p@marketinsightsreports.com or sales@marketinsightsreports.com to get free sample of this report. #sales #researchreports #Clinical #Pharma #drugs #Bloodtest

Have you ever stopped to consider why big pharma companies dominate the market with such towering presence? It's a question that often leads to a labyrinth of complexities, but at its core, the answer lies in the colossal costs of innovation. The journey from a molecule to a medicine is nothing short of an odyssey. For every successful drug that reaches the market, thousands falter and fade away in the rigorous process of research and development. This is not merely a quest of scientific exploration but also a colossal financial gamble. The costs of drug discovery are astronomical, often soaring into billions for a single successful medication. This high-stakes environment demands immense resources, and it's here that the giants of the pharmaceutical industry step in. But the expenditure doesn't halt at discovery. Before a drug can touch lives, it must endure the crucible of clinical trials, a phase that is as financially draining as it is essential. Each stage of a trial, from the initial safety assessments to the expansive patient trials, is a multi-year, multi-million-dollar undertaking. The price tag of these trials reflects not just the cost of medical and scientific manpower but also the value of thoroughness and safety. The enormity of these investments explains why when a drug finally emerges triumphant, its price can be staggering. It's not merely a reflection of the drug's value but also a recoupment of the vast expenses incurred along its journey. This economic reality shapes the pharmaceutical landscape, erecting barriers that only the most financially robust can surmount. In a world where health is paramount, understanding the economics of drug development is crucial. It's a narrative of financial enormity, but also one of hope, where every dollar spent brings us closer to the next medical breakthrough. As we critique and comprehend these pharmaceutical titans, we pave the way for a future where innovation and accessibility can coexist harmoniously. #PharmaInnovation #healthcareinnovation #drugdiscovery #biotechinnovat #NEBULABIOTECH #NEBULAAI

🌟 Exciting Updates from Our CEO360 Life Sciences Group Meeting! 🌟 Earlier this week, we were thrilled to host an enlightening and full house of life sciences CEOs for our monthly CEO360 meeting. A standout moment was when Lisa Caralli, Sr. Director of Scientific Advisory Pharmaceutics at Catalent Pharma Solutions, spearheaded an engaging discussion on "Turning Molecules Into Medicines." Lisa eloquently highlighted the critical role of Target Product Profiles (TPP) and dose design in the successful manufacturing of drug products. She detailed how understanding these elements is vital for Life Sciences CEOs, especially when discussing manufacturing viability with potential investors. Our conversation delved into the complexities and costs associated with manufacturing, underscoring the necessity for CEOs to grasp these aspects thoroughly. This understanding is crucial not only for medication delivery but also for reimbursement strategies. A big thank you to Tari Suprapto, David H. Crean, and John Foley for their invaluable guidance in navigating the intricate journey of manufacturing. Their expertise, coupled with Catalent's vast resources, is equipping early-stage CEOs for successful investor discussions. 🙏 Heartfelt thanks to Lisa for her informative and impactful session, and to our partner sponsors and advisors in the ecosystem, including Catalent Pharma Solutions, Procopio, Cory, Hargreaves & Savitch LLP, Deloitte, Ty Summerlin, CFP®, Arrow Up Partners, LLC LLC, and Cardiff Advisory LLC. Your support is pivotal in empowering our Life Sciences community. Let's continue to foster innovation, share knowledge, and drive the Life Sciences sector forward. Together, we're making a difference! #LifeSciences #Biotechnology #Pharmaceuticals #MedicalDevices #Mentoring #VentureCapital #CapitalRaising

The negotiation techniques you use can have an enormous impact on the success (or failure) of your negotiation. These past two days our CEOs had the opportunity to explore and discuss the merits of different negotiation techniques in different situations. Our workshop concluded with a mock negotiation between a CMO and a Pharma company: Imagine a virtual room full of experienced biotech and medtech CEOs, pretending to be big Pharma and getting their teeth into a deal. Thank you Dr. Florian Burgdorf it was a lot of fun and great learning. You are a super engaging coach, we loved your pointers and the many real world examples. And thank you Sven Fraterman and Gerd W. and BCG on Health Care for setting this up for us. Get ready big #Pharma, #CMOs and #VCs. Next time you have a LifeScience ORG CEO sitting on the other side of the #negotiation table, you are in for a treat. 😉 The recording and the templates are uploaded inside the community. Join the conversation: www.lifescienceorg.com #biotechnology #medtech #lifesciences #ceos #negotiation

Austria is leading the way in Europe’s life sciences landscape, boasting a significant number of biotech, pharmaceutical, and medical technology enterprises 🧬 Acknowledging Austria’s pivotal role, we hosted our very own BOLD Salon to gather insights from both international and local BOLD Minds who are actively shaping the economy of tomorrow. During our BOLD Salon, we curated three engaging sessions, where BOLD Minds leading diverse fields exchanged ideas on healthcare and innovations within the medical sector 👩⚕️ Listen to BOLD Mind, Julie Rosser, CEO at Pregenerate Inc., who co-hosted a stimulating discussion on the potential of #AI to enhance and disrupt healthcare and medicine when integrated with other technologies. How do you envision technology improving healthcare in the future? Share your thoughts below! #BOLDCommunity #BOLDSalon #healthcare #innovations #medicalcare #medicine